Effects of mirabegron: A Synthesis of Findings from 20 Studies

  1. Home
  2. Effects of mirabegron
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of mirabegron: A Synthesis of Findings from 20 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of mirabegron: A Synthesis of Findings from 20 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Mirabegron is a β3-adrenoceptor agonist approved for the treatment of overactive bladder. Studies have shown that mirabegron may have beneficial effects on metabolic and cardiovascular health in addition to improving overactive bladder symptoms.

Mirabegron has the potential to improve obesity and insulin resistance by stimulating brown adipose tissue activity and increasing energy expenditure. 15 It also shows promise for the treatment of heart failure and has been shown to improve doxorubicin-induced cardiomyopathy. 4 Furthermore, mirabegron may be effective in treating neurogenic lower urinary tract dysfunction, such as urinary incontinence, urinary tract infections, and kidney failure. 2

However, mirabegron has also been suggested to cause certain side effects. 19 These side effects include gastrointestinal symptoms (constipation, abdominal pain, vomiting), cardiovascular symptoms (tachycardia, increased blood pressure), and psychiatric symptoms (anxiety, insomnia).

Benefits and Risks

Benefit Summary

Mirabegron can improve overactive bladder symptoms and may improve metabolic and cardiovascular health. It holds promise for the treatment of obesity, insulin resistance, and heart failure. It may also be effective in treating neurogenic lower urinary tract dysfunction.

Risk Summary

Mirabegron has the potential to cause side effects such as gastrointestinal symptoms, cardiovascular symptoms, and psychiatric symptoms.

Comparison of Studies

Commonalities

Many studies suggest that mirabegron activates β3-adrenoceptors and increases energy expenditure, potentially having beneficial effects on metabolic and cardiovascular health.

Differences

The degree of mirabegron's effects and side effects vary across studies. This is likely due to differences in the study populations, dosages, and durations of the studies.

Consistency and Discrepancies of Results

Mirabegron is approved for treating overactive bladder, but further research is needed to fully understand its effects on metabolism and the cardiovascular system.

Considerations for Real-Life Application

Mirabegron should be used as directed by a doctor for the treatment of overactive bladder. Due to its potential impact on metabolic and cardiovascular health, individuals with conditions such as diabetes or heart failure should consult their doctor before using mirabegron.

Limitations of Current Research

Long-term effects and safety of mirabegron have not been fully investigated. Additionally, mirabegron may not be effective for all patients, and the risk of side effects must be considered.

Future Research Directions

Further studies are needed to evaluate the long-term effects and safety of mirabegron. Research is also needed to identify patients who will benefit most from mirabegron therapy.

Conclusion

Mirabegron is a medication approved for treating overactive bladder that may have beneficial effects on metabolic and cardiovascular health. However, it is important to be aware of potential side effects and use it as directed by a doctor.

Literature analysis of 20 papers
Positive Content
20
Neutral Content
0
Negative Content
0
Article Type
2
0
0
1
20
1.

Mirabegron displays anticancer effects by globally browning adipose tissues.

Author: SunXiaoting, SuiWenhai, MuZepeng, XieSisi, DengJinxiu, LiSen, SekiTakahiro, WuJieyu, JingXu, HeXingkang, WangYangang, LiXiaokun, YangYunlong, HuangPing, GeMinghua, CaoYihai

Cancer treatment
Drug repurposing
None mentioned

This study found that mirabegron, a drug used to treat overactive bladders, can effectively treat various cancers by browning adipose tissues. This process increases energy expenditure and reduces tumor growth. The study suggests that mirabegron represents a new paradigm for treating cancer by targeting adipose metabolism.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Effects of chronic mirabegron treatment on metabolic and cardiovascular parameters as well as on atherosclerotic lesions of WHHL rabbits with high-fructose high-fat diet-induced insulin resistance.

Author: MoughaizelMichelle, DagherElie, BouhsinaNora, LalanneValérie, ThorinChantal, DesfontisJean-Claude, MallemM Yassine

Cardiovascular protection
Metabolic syndrome treatment

Mirabegron, a beta-3 adrenergic receptor agonist, has potential therapeutic benefits for metabolic syndrome and its cardiovascular consequences.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.

Author: FreiwanMarah, KovácsMónika G, KovácsZsuzsanna Z A, SzűcsGergő, DinhHoa, LosoncziRéka, SiskaAndrea, KristonAndrás, KovácsFerenc, HorváthPéter, FöldesiImre, CserniGábor, DuxLászló, CsontTamás, SárközyMárta

Cardiac function improvement
Cardiotoxicity prevention
Drug interactions
Potential side effects

Mirabegron and its combination with losartan may be promising therapeutic tools against doxorubicin-induced chronic cardiotoxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Effects of mirabegron on depression, anxiety, learning and memory in mice.

Author: TanyeriMehmet H, BuyukokurogluMehmet E, TanyeriPelin, MutluOguz, OzturkAykut, YavuzKubra, KayaRumeysa K

Improved anxiety
Improved depression
Improved memory
None mentioned

Mirabegron is a drug used to treat overactive bladder. The study found that mirabegron can improve depression and anxiety in mice, and it does not seem to affect learning or memory.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Protocol for the Stimulating &#946;<sub>3</sub>-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease.

Author: BubbKristen J, HarmerJason A, FinemoreMeghan, AitkenSarah Joy, AliZara S, BillotLaurent, ChowClara, GolledgeJonathan, MisterRebecca, GrayMichael P, GrieveStuart M, HamburgNaomi, KeechAnthony C, PatelSanjay, PuttaswamyVikram, FigtreeGemma A

Improved walking distance

Mirabegron, a β<sub>3</sub>-adrenergic receptor agonist, is being investigated as a potential treatment for intermittent claudication, a common symptom of peripheral artery disease. The STAR-PAD trial will evaluate whether mirabegron can improve walking distance in patients with intermittent claudication.

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.

Author: KovácsZsuzsanna Z A, SzűcsGergő, FreiwanMarah, KovácsMónika G, MárványköviFanni M, DinhHoa, SiskaAndrea, FarkasKatalin, KovácsFerenc, KristonAndrás, HorváthPéter, KőváriBence, CserniBálint Gábor, CserniGábor, FöldesiImre, CsontTamás, SárközyMárta

Diastolic dysfunction
Left ventricular hypertrophy
Uremic cardiomyopathy

Losartan, an angiotensin-II receptor blocker, effectively reduces diastolic dysfunction, left ventricular hypertrophy, and fibrosis in uremic cardiomyopathy. Mirabegron, a β3-AR agonist, shows some improvement in diastolic dysfunction and fibrosis, but does not improve eNOS expression.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue.

Author: Peres Valgas da SilvaCarmem, CalmasiniFabiano, AlexandreEduardo Costa, RaposoHelena Fonseca, DelbinMaria Andreia, MonicaFabiola Zakia, ZanescoAngelina

Improved metabolism
Increased energy expenditure

This study investigates the effects of mirabegron, a medication used to treat overactive bladder, on metabolic health in mice with diet-induced obesity. The study found that mirabegron improved energy expenditure and decreased adiposity in obese mice.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Effects of mirabegron on JJ stent-related symptoms: A multicentric study.

Author: CinarOnder, TanidirYiloren, OzerSelcuk, CizmeciSezer, ErbatuOguzcan, OzdemirTuran, GirginReha, OngunSakir, UcerOktay, KizilayFuat, SenVolkan, IrerBora, BozkurtOzan,

Improved quality of life
Improved stent-related symptoms

Daily use of 50 mg of mirabegron significantly improved stent-related symptoms, sexual matters, and quality of life in patients who underwent ureteroscopic stone surgery.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

11.

The metabolic effects of mirabegron are mediated primarily by &#946;<sub>3</sub> -adrenoceptors.

Author: DehvariNodi, SatoMasaaki, BokhariMuhammad Hamza, KalinovichAnastasia, HamSeungmin, GaoJie, NguyenHuong T M, WhitingLynda, MukaidaSaori, MerlinJon, ChiaLing Yeong, WoottenDenise, SummersRoger J, EvansBronwyn A, BengtssonTore, HutchinsonDana S

Glucose homeostasis

This study investigated the effect of the β3-adrenoceptor agonist mirabegron on glucose homeostasis in vitro and in vivo. Mirabegron was found to improve glucose handling in vivo, primarily through actions at the β3-adrenoceptor.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies.

Author: SugayaKimio, YamagamiHidetomi, NishijimaSaori, KadekawaKatsumi, HizueMasanori, ItoYoshihiko, YamadaShizuo

Bladder capacity

A combination of 5-hydroxymethyl tolterodine and mirabegron showed potential synergistic effects in a rat model of pelvic congestion, suggesting a possible treatment strategy for this condition.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice.

Author: HaoLei, ScottSheyenne, AbbasiMehrnaz, ZuYujiao, KhanMd Shahjalal Hossain, YangYang, WuDayong, ZhaoLing, WangShu

Improved glucose tolerance
Improved insulin sensitivity
Obesity prevention

Mirabegron, a β3-adrenergic receptor agonist, promoted browning of white adipose tissue and improved glucose tolerance and insulin sensitivity in mice. This study suggests that mirabegron might be a potential therapeutic option for treating obesity and related metabolic disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.

Author: KinjoManami, YamaguchiTsuyoshi, TamboMitsuhiro, OkegawaTakatsugu, FukuharaHiroshi

Improved OAB symptoms
Reduced anxiety

Mirabegron improved OAB symptoms, anxiety, and depression symptoms in treatment-naïve women with OAB. Anxiety symptoms, but not depression symptoms, were significantly correlated with OAB symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle.

Author: MakiTomoko, KajiokaShunichi, ItsumiMomoe, KaremanEljamal, LeeKen, ShiotaMasaki, EtoMasatoshi

Detrusor relaxation

Mirabegron is a medication used to treat overactive bladder. This study investigates the mechanism by which mirabegron relaxes detrusor smooth muscle, which is the muscle responsible for bladder contraction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Acute metabolic and cardiovascular effects of mirabegron in healthy individuals.

Author: LohRebecca K C, FormosaMelissa F, La GercheAndre, ReutensAnne T, KingwellBronwyn A, CareyAndrew L

Increased energy expenditure
Increased supraclavicular skin temperature
Increased blood pressure
Increased heart rate

A 100-mg dose of mirabegron increases energy expenditure and supraclavicular skin temperature in a β3-adrenoceptor-specific manner without increasing blood pressure or heart rate.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Mirabegron: potential off target effects and uses beyond the bladder.

Author: DehvariNodi, da Silva JuniorEdilson Dantas, BengtssonTore, HutchinsonDana Sabine

Metabolic disease treatment
Mirabegron off-target effects

This review discusses the use of mirabegron, a drug originally developed to treat overactive bladder, for other conditions, including heart failure and metabolic disease. Mirabegron is a beta-3 adrenoceptor agonist, a type of receptor that has been shown to improve metabolic function in animal studies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.

Author: HsiaoSheng-Mou, ChangTing-Chen, ChenChi-Hau, WuWen-Yih, LinHo-Hsiung

Overactive bladder treatment

This study compared the clinical outcomes and urodynamic effects of mirabegron and tolterodine treatment for women with overactive bladder syndrome (OAB).

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.